Capricor's Stock Plummets Amid FDA Review for DMD Therapy
By ATTN Desk · Editorial oversight: Sean Han
Introduction
Capricor Therapeutics Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology company headquartered in San Diego, California. The firm develops cell and exosome-based therapies aimed at serious diseases, with a primary focus on Duchenne muscular dystrophy (DMD). Its multi-stage pipeline utilizes allogeneic cardiosphere-derived cells (CDCs) and engineered exosomes to address unmet medical needs.
Corporate Structure
Founded in 2005, Capricor employs between 51 and 200 staff members across research, clinical operations, and corporate functions. The company’s management team includes specialists in translational research and cell therapy development. Capricor’s equity incentive plan, approved by shareholders in June 2025, authorizes the issuance of 3,500,000 common shares to align employee interests with long-term growth objectives.
Duchenne muscular dystrophy by Inge Poelman
Developments and News
On May 13, 2025, Capricor indicated that its first-quarter 2025 financial results would be released on the same day, followed by a conference call at 4:30 p.m. ET.
On May 27, 2025, the company filed a Form 8-K disclosing board-level changes (Items 5.02 and 5.07). Details on director elections and shareholder votes were made available through the SEC.
On June 16, 2025, Capricor’s S-8 registration became effective, facilitating the 2025 Equity Incentive Plan to reward employees with common stock.
On July 11, 2025, a Form 8-K (Items 7.01 and 9.01) was filed, reflecting Regulation FD disclosures and the inclusion of exhibits related to material events.
Capricor announced on LinkedIn that the FDA had granted Priority Review to its DMD cell therapy, Deramiocel, with a target action date of August 31, 2025. The post also highlighted open-label extension data from the HOPE-2 study and the granting of Orphan Drug Designation for Becker muscular dystrophy. Additionally, the company appointed Dr. Michael Binks as Chief Medical Officer, effective in June 2025.
Financial and Strategic Analysis
As of July 11, 2025, CAPR shares closed at USD 7.08, down 37.89% from the prior session, with a volume of 2,408,681 shares. Key metrics from Yahoo Finance include:
| Metric | Value |
|---|---|
| Previous Close (USD) | 11.94 |
| Day’s Range (USD) | 6.07 – 11.46 |
| 52-Week Range (USD) | 3.52 – 23.40 |
| Market Cap | USD 377.55 million |
| Revenue (TTM) | USD 17.36 million |
| Net Income (TTM) | –USD 55.06 million |
| Total Cash (MRQ) | USD 144.78 million |
| Total Debt/Equity (MRQ) | 0.98% |
| EPS (TTM) | –1.37 |
| 1-Year Target Estimate | USD 42.12 |
The company maintains cash reserves supported by its recent equity plan and a low debt ratio. Its pipeline diversification—spanning cell therapies and exosome platforms—aims to mitigate single-product risk and position Capricor within the rare disease segment.
Market Position and Industry Context
Operating in the biotechnology research sector, Capricor competes with firms developing biologics and gene therapies for neuromuscular disorders. The FDA’s Priority Review for Deramiocel reflects the regulatory focus on this therapy. The Orphan Drug Designation for Becker muscular dystrophy extends Capricor’s neuromuscular portfolio. Academic partnerships and a translational research approach contribute to its standing among early-stage cell and exosome therapy developers.
tl;dr
On July 11, 2025, Capricor filed an 8-K under Items 7.01 and 9.01 following material disclosures. Its stock trades at USD 7.08, down 37.89% intraday, with a market cap of USD 377.6 million. The FDA has set an August 31, 2025, action date for the Priority Review of Deramiocel in Duchenne muscular dystrophy. The company plans to release second-quarter 2025 results in August and maintains a 2025 Equity Incentive Plan to issue 3.5 million shares.